ReviewCureus2019
Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology.
Review in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Adjunctive efficacy of Bifidobacterium animalis subsp. lactis XLTG11 for functional constipation in children.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Trial
- Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel syndrome subtypes.Internal and emergency medicine · 2026Review
- Fructose malabsorption associated with functional abdominal bloating: Case-control study.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Multi-meta-omics reveal distinct microbial genomic profiles and metabolic dysregulation in non-celiac gluten sensitivity.mSphere · 2026Article
- Unraveling the Complexities of Small Intestinal Bacterial Overgrowth.Medicina (Kaunas, Lithuania) · 2026Review
- Small intestinal microbiome, the underrated maestro of SIMO disease.FEMS microbiology reviews · 2026Review
- Microbiota-immune-enteric nervous system interactions in functional constipation: a narrative review and hypothesis-generating framework.Frontiers in immunology · 2026Review
- The gut methanotroph Methylocystis intestini modulates intestinal peristalsis and fat metabolism via reducing methane levels.Nature communications · 2025Article
- Altered gut microbial functional pathways in people with irritable bowel syndrome enable precision health insights.BMC gastroenterology · 2025Article
- Optimizing Nutritional Balance: Integrating the Mediterranean Diet into Low-FODMAP Nutrition.Microorganisms · 2025Review
- Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.Frontiers in immunology · 2025Review
- Functional Gastrointestinal Disorders and Childhood Obesity: The Role of Diet and Its Impact on Microbiota.Nutrients · 2024Review
- The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome.Journal of clinical medicine · 2024Review
- Supplementation of a High-Fat Diet with Pentadecylresorcinol Increases the Representation ofInternational journal of molecular sciences · 2024Article
- The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Observational
- The Underrated Gut Microbiota Helminths, Bacteriophages, Fungi, and Archaea.Life (Basel, Switzerland) · 2023Review
- Ability of lactulose breath test results to accurately identify colorectal polyps through the measurement of small intestine bacterial overgrowth.World journal of gastrointestinal surgery · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional gut disorders have long known to cause depravity in quality of life. Among the group of these heterogeneous disorders, irritable bowel syndrome (IBS) has been known to affect a large chunk of our population. IBS is not as simple as it sounds. Caused by a multitude of factors, the heterogeneity of this disorder has laid the foundation for research and the new principles of neurogastroenterology. Dysbiosis and methane production are one of the forthcoming factors that are currently under investigation. Down the road of exclusive enteric anaerobic fermentation of polysaccharides, methane is produced. It was considered to be an inert gas in the past, with little to no role in gut activity but now it is established that it has an impressive role in the etiology of constipation-predominant IBS (C-IBS). Acting as a neurotransmitter, it is known to affect ileal and colonic transit time, which has currently been shown in animal studies. Many laxatives, ionophore antibiotics, drugs like rifamixin and neomycin have been targeted against this very principle. Lately, lovastatin has emerged as a potential pharmacologic therapy to devoid the gut of methane without disrupting the gut niche in itself and has shown promise in relieving the symptoms of C-IBS. The goal of this article is to compile and assemble the literature available on IBS and the neuromodulation of methane to teach physicians and research scientists about the current age of gastroenterology and the growing need to emphasize the role of methane in the symptomatology of functional gut disorders like C-IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.